Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Majadahonda – page 38

470 clinical trials in Majadahonda, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Majadahonda at a glance
470
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

470 trials in Majadahonda

Open in trial search

Non-small cell lung cancer

Not recruiting

Study Comparing Chemotherapy with Nivolumab to Chemotherapy Alone for Patients with Resectable Non-small Cell Lung Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Lung squamous cell carcinoma stage III+1

Not recruiting

Study on the Effect of Ivonescimab, Pemetrexed, and Carboplatin in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutation After Previous Treatment

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Summit Therapeutics Inc.

Colorectal cancer metastatic+1

Not recruiting

Study on the Effectiveness of Ompenaclid with FOLFIRI and Bevacizumab for Patients with Advanced or Metastatic Colorectal Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Inspirna Inc.

Hepatocellular carcinoma

Not recruiting

Study of Pembrolizumab and Lenvatinib with TACE for Patients with Incurable Non-metastatic Liver Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Merck Sharp & Dohme LLC

Hepatic encephalopathy

Not recruiting

Study on Rifaximin for Delaying Hepatic Encephalopathy in Cirrhosis Patients

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Rifaximin
  • Sponsor:Salix Pharmaceuticals Inc.

Marginal zone lymphoma+1

Not recruiting

Study Comparing Zanubrutinib, Obinutuzumab, and Rituximab with Lenalidomide and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:BeOne Medicines AG

Breast cancer metastatic+1

Not recruiting

Study of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Breast Cancer Resistant to Trastuzumab, Pertuzumab, and Taxane Treatment

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer De Mama

Dilated cardiomyopathy

Not recruiting

Study on Danicamtiv for Patients with Primary Dilated Cardiomyopathy Due to MYH7 or TTN Gene Variants

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Danicamtiv
  • Sponsor:Myokardia Inc.

Metabolic dysfunction-associated steatohepatitis+1

Not recruiting

Study on Efinopegdutide and Semaglutide for Adults with Non-Alcoholic Steatohepatitis (NASH) Before Cirrhosis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Efinopegdutide
  • Sponsor:Merck Sharp & Dohme LLC

Macular oedema+1

Not recruiting

Study on the Effectiveness and Safety of Aflibercept for Patients with Vision Loss Due to Macular Edema from Retinal Vein Blockage

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Bayer AG

Cytomegalovirus infection+1

Not recruiting

Study on Letermovir for Preventing CMV Infection in Lung Transplant Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Letermovir
  • Sponsor:Fundacion Para La Investigacion Biomedica De Cordoba

Non-small cell lung cancer

Not recruiting

Study of Belrestotug and Dostarlimab for Patients with Untreated Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Majadahonda

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on ATTR amyloid cardiomyopathy, evaluating new therapeutic approaches for both hereditary and wild-type variants of this heart condition.

  • Heart Disease Management
  • Cardiac Function Assessment
  • Disease Markers Evaluation

Multiple trials testing novel compounds to improve patient outcomes and quality of life.

02 Infectious Disease Prevention

Comprehensive vaccine development programs targeting urinary tract infections and various herpes virus strains, including studies on both prevention and treatment.

  • UTI Prevention
  • Herpes Zoster Protection
  • Immunotherapy Development

Focus on long-term efficacy and immune response in different age groups.

03 Oncology Studies

Advanced research in multiple cancer types, including prostate cancer, gastric cancer, and lymphomas, with emphasis on targeted therapies and combination treatments.

  • Metastatic Disease Treatment
  • Novel Drug Combinations
  • Immunotherapy Approaches

Investigating breakthrough treatments for various stages of cancer progression.

04 Neurological Disorders

Pioneering research in cerebral ischemic stroke and multiple sclerosis, evaluating innovative treatments to improve patient outcomes and disease management.

  • Stroke Treatment
  • Progressive MS Management
  • Functional Recovery

Focus on both acute interventions and long-term disease modification.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.